OncoHost will present innovative research at ISLB 2026, showcasing plasma proteomics for early detection of immunotherapy resistance in NSCLC.

OncoHost has unveiled groundbreaking research on TKI sensitivity in metastatic renal cell carcinoma at the ESMO 2026 Congress, aiding personalized treatment decisions.

OncoHost's upcoming presentation at WCLC 2026 aims to showcase the efficacy of PROphetNSCLC® in predicting patient outcomes during treatment cycles, enhancing precision oncology.

With the permit, the Israeli company can offer its plasma proteomics ProphetNSCLC test for guiding therapy in lung cancer patients throughout New York State.

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

The partners will study the use of a test for Ly6E(hi) neutrophils as a biomarker for treatment response in five cancer indications.

ஒரு தசாப்தத்திற்கும் மேலாக, NoCamels இஸ்ரேலின் உயர்-தொழில்நுட்பத் துறையின் ஒவ்வொரு அம்சத்தையும் பற்றி எழுதியுள்ளது, கொடிய நோய்களுக்கான சிகிச்சைக்கான மருத்துவ முன்னேற்றங்கள் முதல் வேலை மற்றும் ஓய்வு மற்றும் நமது போராடும் கிரகத்தைப் பாதுகாக்க கிரீன்டெக் ஆகிய இரண்டிற்கும் டிஜிட்டல் முன்னேற்றங்கள் வரை. எங்களிடமிருந்து ஐந்து பிடித்தவை மற்றும் எங்கள் விசுவாசமான வாசகர்களான உங்களிடமிருந்து ஐந்து பிடித்தவை இங்கே: எங்கள் தேர்வுகள்: புற்று நோய் குணமாகும் செயற்கை நுண்ணறிவு நம் வாழ்வில் எப்போதும் அதிகரித்து வரும் பங்கு வகிக்கிறது, medtech நிறுவனம் OncoHost புற்றுநோயியல் நிபுணர்கள் தங்கள் புற்றுநோயாளிகளுக்கு உகந்த சிகிச்சையை தீர்மானிக்க இதைப் பயன்படுத்துகின்றனர்.

A new chapter for immunotherapy decision-making Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost? Conventional, tumor centric assays such as PD-L1 immunohistochemistry, tumor-mutational burden (TMB), and next-generation sequencing (NGS) provide valuable clues, but […]

OncoHostがISLBで発表。AI血漿プロテオミクスで非小細胞肺がんの治療効果を早期予測、医療に革新をもたらす。

OncoHost has won a €2.5m ($2.8m) grant to develop a novel biomarker capable of predicting cancer patient responses to immunotherapy.

OncoHost's groundbreaking study on proteomic aging biomarkers will be featured at AACR 2026, highlighting immunotherapy outcomes in various cancers.

OncoHost has been recognized with the 2026 Artificial Intelligence Excellence Award in the health sector for its groundbreaking AI technologies in oncology.

OncoHost's groundbreaking study highlights a new framework for integrating serum and plasma proteomic datasets, transforming biomarker research in oncology.

OncoHost has received the 2026 BIG Innovation Award in the Health category, celebrating its pioneering work in precision medicine and clinical outcomes.

OncoHost has been recognized with a Gold Award at the 2025 Merit Awards for Healthcare due to its innovative proteomics platform, PROphet®.

OncoHost, a pioneering tech firm, has been awarded 'Proteomics Innovation of the Year' by BioTech Breakthrough. This honor highlights their groundbreaking advancements in precision medicine and patient care.

OncoHost showcases two innovative studies on plasma proteomics for non-small cell lung cancer monitoring and prediction at ISLB 2025, highlighting a transformative approach.

OncoHost has secured a New York State laboratory permit, enabling the use of its innovative PROphetNSCLC test, enhancing precision oncology access.

OncoHost announces exciting new research at ESMO 2025, focusing on innovative plasma proteomics for treatment selection in melanoma patients.

OncoHost's pivotal research on small cell lung cancer subtypes will be presented at WCLC 2025, showcasing advancements in precision medicine and patient outcomes.

OncoHost has been awarded as the premier precision oncology solution for 2025 by Life Sciences Review, highlighting its innovative approach to cancer treatment.

OncoHost has been awarded the Gold Winner status in the 2025 Merit Awards for its significant advancements in precision medicine research and development, reflecting its innovative contributions to healthcare.

Discover groundbreaking insights from OncoHost's study on treatment resistance in lung cancer, utilizing proteomics and AI for personalized therapy.